Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 46, 2013, Pages 18638-18643

  Xu, Xiaoyang ^a,b   Xie, Kun ^b   Zhang, Xue Qing ^a   Pridgen, Eric M ^c   Park, Ga Young ^b   Cui, Danica S ^a   Shi, Jinjun ^a   Wu, Jun ^a   Kantoff, Philip W ^d   Lippard, Stephen J ^b   Langer, Robert ^b,c   Walker, Graham C ^b   Farokhzad, Omid C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemosensitivity; Combination therapy; SiRNA delivery

Indexed keywords

CISPLATIN; DNA POLYMERASE REV1; MACROGOL; NANOPARTICLE; POLYGLACTIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUPPRESSOR GENE; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

CHEMOSENSITIVITY; COMBINATION THERAPY; SIRNA DELIVERY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; GENE SILENCING; HUMANS; LUCIFERASES; NANOPARTICLES; PLATINUM; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84887443743     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303958110     Document Type: Article

References (32)

1. Woodcock J, Griffin JP, Behrman RE (2011) Development of novel combination therapies. N Engl J Med 364(11):985-987.
2. Jia J, et al. (2009) Mechanisms of drug combinations: Interaction and network perspectives. Nat Rev Drug Discov 8(2):111-128.
3. Ryan CJ (2013) Clinical trial design strategies in the post-abiraterone/enzalutamide setting. 2013 Genitourinary Cancers Symposium Proceedings, ed Carducci MA (American Society of Clinical Oncology, Alexandria, VA), pp 26-28.
4. Ahmad S (2010) Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers 7(3):543-566.
5. Zhao Y, et al. (2012) Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatin. Proc Natl Acad Sci USA 109(19):7269-7274.
6. Xie K, Doles J, Hemann MT, Walker GC (2010) Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci USA 107(48):20792-20797.
7. Doles J, et al. (2010) Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci USA 107(48):20786-20791.
8. Wang H, et al. (2009) REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy. Neuro Oncol 11(6):790-802.
9. Fire A, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806-811. (Pubitemid 28099681)
10. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10(11):1187-1189. (Pubitemid 39540433)
11. Lage H (2006) MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 7(7):813-821.
12. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov 8(2):129-138.
13. Zheng D, et al. (2012) Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci USA 109(30):11975-11980.
14. Davis ME, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067-1070.
15. Woodrow KA, et al. (2009) Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 8(6):526-533.
16. Zhang XQ, et al. (2011) Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy. Adv Mater 23(41):4770-4775.
17. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16-20.
18. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY (2006) Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 5(10):791-796. (Pubitemid 44570860)
19. Zhang XQ, et al. (2012) Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev 64(13):1363-1384.
20. MacDiarmid JA, et al. (2009) Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 27(7):643-651.
21. Sun TM, et al. (2011) Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 5(2):1483-1494.
22. Xiong XB, Lavasanifar A (2011) Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 5(6):5202-5213.
23. Farokhzad OC (2008) Nanotechnology for drug delivery: The perfect partnership. Expert Opin Drug Deliv 5(9):927-929.
24. Hrkach J, et al. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra139.
25. Kolishetti N, et al. (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107(42):17939-17944.
26. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC (2011) Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108(5):1850-1855.
27. Love KT, et al. (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107(5):1864-1869.
28. Giandomenico CM, et al. (1995) Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents. Inorg Chem 34(5):1015-1021.
29. Zhang Z, Feng SS (2006) In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules 7(4):1139-1146. (Pubitemid 43670800)
30. Washington MT, Carlson KD, Freudenthal BD, Pryor JM (2010) Variations on a theme: Eukaryotic Y-family DNA polymerases. Biochim Biophys Acta 1804(5):1113-1123.
31. Gan GN, Wittschieben JP, Wittschieben BO, Wood RD (2008) DNA polymerase zeta (pol zeta) in higher eukaryotes. Cell Res 18(1):174-183.
32. Reedijk J (1999) Why does Cisplatin reach Guanine-n7 with competing s-donor ligands available in the cell? Chem Rev 99(9):2499-2510.